• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌 Gleason 评分 7 级升级是否总是预示着更差的预后?

Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?

机构信息

Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Clin Genitourin Cancer. 2023 Dec;21(6):e412-e421. doi: 10.1016/j.clgc.2023.05.002. Epub 2023 May 7.

DOI:10.1016/j.clgc.2023.05.002
PMID:37248147
Abstract

OBJECTIVE

To determine the clinical significance of Gleason score(GS) 7 upgraded on radical prostatectomy(RP) and its impact on the prognosis of patients.

PATIENTS AND METHODS

We used the Surveillance, Epidemiology, and End Results (SEER) database to study 8832 men diagnosed with M0 GS 3+4/4+3 prostate cancer (PCa) from 2010 to 2015 treated by RP. Logistic regression was used to analyze the effect of clinicopathological characteristics on the Gleason sore upgraded. Cox hazards regression analysis was performed to find significant factors of overall survival (OS).

RESULTS

A total of 6237 (70.6%) biopsy GS 3+4 patients and 2595(29.4%) biopsy GS 4+3 patients were included in the study. Univariate and multivariate logistic regression analysis found that prostate-specific antigen (PSA)>20ng/ml, T stage 3-4, lymph node metastasis are independent risk factors in predicting the incidence of GS upgraded after RP (all P<0.05). Through multivariate analysis, we found that black race, GS upgraded, chemotherapy played significant roles in predicting poor OS (all P<0.05). It was surprising to find that the biopsy GS upgraded in patients with PSA 0-4ng/ml and 4.1-10ng/ml had a significant association with poor OS (all P<0.05). Multivariate analysis showed that only in patients with PSA 4-10ng/ml, biopsy GS upgrade had a statistically important relationship with poor OS (P=0.046).

CONCLUSIONS

Not all patients with GS 7 upgraded had a worse prognosis than those without GS upgraded. Only in patients with PSA 4.1-10ng/ml, biopsy GS 7 upgraded was an independent risk factor affecting OS.

摘要

目的

确定前列腺根治性切除术(RP)后 Gleason 评分(GS)升级 7 的临床意义及其对患者预后的影响。

患者与方法

我们使用监测、流行病学和最终结果(SEER)数据库研究了 2010 年至 2015 年间接受 RP 治疗的 8832 名诊断为 M0 GS 3+4/4+3 前列腺癌(PCa)的男性患者。使用逻辑回归分析临床病理特征对 Gleason 评分升级的影响。采用 Cox 风险回归分析寻找总生存(OS)的显著因素。

结果

共纳入 6237 例(70.6%)活检 GS 3+4 患者和 2595 例(29.4%)活检 GS 4+3 患者。单因素和多因素逻辑回归分析发现,前列腺特异性抗原(PSA)>20ng/ml、T 分期 3-4 期、淋巴结转移是预测 RP 后 GS 升级发生率的独立危险因素(均 P<0.05)。通过多因素分析,我们发现黑种人、GS 升级、化疗在预测不良 OS 中起重要作用(均 P<0.05)。令人惊讶的是,在 PSA 0-4ng/ml 和 4.1-10ng/ml 的患者中,活检 GS 升级与不良 OS 显著相关(均 P<0.05)。多因素分析显示,只有在 PSA 4-10ng/ml 的患者中,活检 GS 升级与不良 OS 有统计学上的显著关系(P=0.046)。

结论

并非所有 GS 7 升级患者的预后均比未升级患者差。只有在 PSA 4.1-10ng/ml 的患者中,活检 GS 7 升级是影响 OS 的独立危险因素。

相似文献

1
Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?前列腺癌 Gleason 评分 7 级升级是否总是预示着更差的预后?
Clin Genitourin Cancer. 2023 Dec;21(6):e412-e421. doi: 10.1016/j.clgc.2023.05.002. Epub 2023 May 7.
2
Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.根治性前列腺切除术后 Gleason 评分升级的临床和病理预测因素:单机构系列研究结果。
Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003. Epub 2009 Oct 17.
3
How significant is upgrade in Gleason score between prostate biopsy and radical prostatectomy pathology while discussing less invasive treatment options?在讨论侵入性较小的治疗方案时,前列腺活检与根治性前列腺切除术病理检查之间的Gleason评分升级有多显著?
Scand J Urol. 2014 Apr;48(2):177-82. doi: 10.3109/21681805.2013.829519. Epub 2013 Aug 14.
4
The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.前列腺特异性抗原(PSA)密度预测初始前列腺活检和前列腺切除术中 Gleason 评分升级的能力随着肿瘤分级的增加而降低,这是由于单位肿瘤体积的 PSA 分泌减少所致。
BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.
5
Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.经直肠超声(TRUS)引导下活检检测到的Gleason 4级形态在预测Gleason评分3 + 4 = 7的前列腺癌升级或分期升高方面的效用
Virchows Arch. 2016 Sep;469(3):313-9. doi: 10.1007/s00428-016-1981-2. Epub 2016 Jul 10.
6
The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer.前列腺癌患者中前列腺穿刺活检与根治性前列腺切除术 Gleason 评分的差异。
Urol J. 2020 Aug 4;18(4):395-399. doi: 10.22037/uj.v16i7.5985.
7
The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy.前列腺癌 Gleason 评分 7 升级对根治性前列腺切除术后生化复发风险的影响。
Biomed Res Int. 2018 Apr 30;2018:4510149. doi: 10.1155/2018/4510149. eCollection 2018.
8
[Clinically predictive factors of Gleason score upgrading in patients after radical prostatectomy].[根治性前列腺切除术后患者 Gleason 评分升级的临床预测因素]
Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Aug 18;48(4):603-606.
9
Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.预测中、高级别前列腺癌患者显著分级变化的前列腺活检临床和病理变量。
BJU Int. 2009 Jan;103(1):43-8. doi: 10.1111/j.1464-410X.2008.08059.x. Epub 2008 Sep 8.
10
Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.从前列腺穿刺活检到根治性前列腺切除术的前列腺癌升级和降级:使用改良的 Gleason 分级系统和考虑三级分级的发生率和预测因素。
Eur Urol. 2012 May;61(5):1019-24. doi: 10.1016/j.eururo.2012.01.050. Epub 2012 Feb 8.

引用本文的文献

1
Overdiagnosis and Overtreatment in Prostate Cancer.前列腺癌的过度诊断与过度治疗
Diseases. 2025 May 24;13(6):167. doi: 10.3390/diseases13060167.